Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23699642 | 0.89 | XDH (0.42) | MAPK1HRH3L3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19808815 | 0.84 | HRH3 (0.47) | MAPK1HRH3LMNAKDM4EL3MBTL1 | |
| SCHEMBL19808881 | 0.83 | GABRA5 (0.42) | MAPK1HRH3LMNAKDM4EL3MBTL1 | |
| SCHEMBL19808807 | 0.83 | LMNA (0.41) | MAPK1HRH3LMNAKDM4EL3MBTL1 | |
| SCHEMBL19808802 | 0.77 | HRH3 (0.42) | MAPK1HRH3LMNAKDM4EL3MBTL1 | |
| SCHEMBL19808916 | 0.74 | MAPK1 (0.42) | MAPK1LMNAKDM4EL3MBTL1GABRA5 | |
| SCHEMBL19808889 | 0.73 | LMNA (0.42) | MAPK1HRH3LMNAKDM4EL3MBTL1 | |
| SCHEMBL18609606 | 0.73 | HTT (0.51) | KDM4EL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL19808827 | 0.73 | HRH3 (0.48) | MAPK1HRH3LMNAKDM4EL3MBTL1 | |
| SCHEMBL19808863 | 0.71 | P2RX3 (0.45) | MAPK1HRH3LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275881-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3275881-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | MAPK1 2748/4885HRH3 41/4885LMNA 2733/4885 |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | HIF1AN, EGLN3, EGLN2 | MAPK1 2748/4885HRH3 41/4885LMNA 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.